Navigation Links
VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease
Date:6/11/2009

of words such as "may," "could," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "continue" or the negative of these terms or other comparable terminology. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond VIA's control and which could materially affect actual results, levels of activity, performance or achievements.

Factors that may cause actual results to differ materially from current expectations include, but are not limited to:

    -- our ability to borrow additional amounts under the loan from Bay City
       Capital, which is subject to the discretion of Bay City Capital;
    -- our ability to obtain necessary financing in the near term, including
       amounts necessary to repay the loan from Bay City Capital by the
       September 14, 2009 maturity date (or earlier if certain repayment
       acceleration provisions are triggered);
    -- our ability to control our operating expenses;
    -- our ability to comply with covenants included in the loan from Bay
       City Capital;
    -- our ability to maintain the listing of our common stock on NASDAQ;
    -- our failure to timely recruit and enroll patients for the FDG-PET
       clinical trial, as well as any future clinical trial;
     -- our failure to obtain sufficient data from enrolled patients that can
       be used to evaluate VIA- 2291, thereby impairing the validity or
       statistical significance of our clinical trials;
    -- our ability to successfully complete our clinical trials of VIA-2291
       on expected timetables and the outcomes of such clinical trials;
    -- complexities in designing and implementing cardiovascular clinical
       trials using histological examinations, measurement of biomarkers,
       medical imaging and atherosclerotic plaque bioassays;

'/>"/>
SOURCE VIA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Oramed Pharmaceuticals to Present at the 8th National Life Science & Technology Week ILSI -BIOMED Conference, Israel 2009
2. Merz Pharmaceuticals Announce Three Studies of NT-201 - (Botulinum neurotoxin type A Free From Complexing Proteins)
3. ISTA Pharmaceuticals Announces Positive Results for Phase 2 Study of Low-Dose Bromfenac in Dry Eye Disease
4. Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting
5. Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical and Absolute Weight Loss and Improvements in Secondary Endpoints Associated with Cardiovascular Risk
6. Access Pharmaceuticals Announces Publication of Thiarabine Combination Data
7. Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials
8. Arena Pharmaceuticals Announces the Presentation of Lorcaserin Phase 3 BLOOM Data at the American Diabetes Associations 69th Scientific Sessions
9. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
10. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
11. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 2014 The global market for human ... introduction of new vaccines. These new products and ... Market. The Kalorama information report examines the global ... developmental vaccines for diseases that are already vaccine-preventable. ... entire communities from diseases spread by person-to-person transmission. ...
(Date:10/27/2014)... , Oct. 27, 2014  RenovoRx, a leading developer ... and delivery of fluids to selected sites in the ... Directors has appointed Shaun Bagai as Chief ... RenovoRx Board of Directors. Bagai brings more than 15 ... Bagai joined RenovoRx in June 2014 and in ...
(Date:10/27/2014)... , Oct. 27, 2014  In the last few weeks, Ebola ... Africa to a worldwide crisis when a traveler ... virus and died, and two nurses were infected. While ... happen, the use of modern technology, such as electronic health records ... This week, InformationWeek Healthcare Editor Alison Diana ...
Breaking Medicine Technology:Vaccines 2014: World Market Analysis, Key Players, Trends, Pediatric and Adult Segments 2Vaccines 2014: World Market Analysis, Key Players, Trends, Pediatric and Adult Segments 3RenovoRx Board Names Shaun R. Bagai as CEO 2EHRs in the Age of Ebola: Discuss on InformationWeek 2EHRs in the Age of Ebola: Discuss on InformationWeek 3
... SAN DIEGO, Jan. 17, 2012  Janssen Research & ... San Diego, a 30,000-square-foot life science innovation center, ... Center.  The innovation center provides a capital efficient, ... technologies and research platforms to advance medical care. ...
... Jan. 17, 2012   ULURU Inc. (NYSE AMEX: ... Melmed Holdings AG for the marketing of Altrazeal® ... Africa has been finalized. Under the terms of ... marketing of Altrazeal® to Melmed Holdings AG, who are establishing ...
Cached Medicine Technology:Janssen Research & Development, LLC Opens JANSSEN LABS at San Diego 2Janssen Research & Development, LLC Opens JANSSEN LABS at San Diego 3Janssen Research & Development, LLC Opens JANSSEN LABS at San Diego 4ULURU Inc. Completes Altrazeal® License Agreement for Europe 2ULURU Inc. Completes Altrazeal® License Agreement for Europe 3
(Date:10/30/2014)... have to be at least 2 years old to ... no official U.S. guidance exists other than the general ... breastfeed for at least the first six months. , ... That,s the question that motivated researchers at the University ... study the eating patterns of American infants at 6 ...
(Date:10/30/2014)... 2014 Nutrition Leaders, a popular online ... aids, and more, is currently hosting a sweepstakes on ... underway, is open to U.S. residents age 18 and ... 2014. One lucky winner will then be selected at ... gift card to NutritionLeaders.com. , Nutrition Leaders’ managing director ...
(Date:10/30/2014)... Burlington, NC (PRWEB) October 30, 2014 ... life, commercial, and health insurance plans for North Carolina ... its satellite office in Burlington’s Holly Hill Mall. The ... 15, with agents already helping customers through all facets ... policy purchase. , Allred Insurance spokesman Scott Allred couldn’t ...
(Date:10/30/2014)... PreDiabetes Centers , the pioneer in prediabetes ... a supply of sugardown®, a chewable dietary supplement that ... spikes. Learning how to control blood sugar levels and ... diabetes prevention plan. , Shoppers who spend $50 or ... sugardown. The offer expires November 30. , Full-size ...
(Date:10/30/2014)... Steven Reinberg HealthDay Reporter , ... to men with prostate cancer who also have certain heart ... cause, a new study suggests. , , The therapy in question ... cancer to reduce levels of male hormones to prevent the ... the current research, this hormone therapy was linked to triple ...
Breaking Medicine News(10 mins):Health News:What do American babies eat? A lot depends on Mom's socioeconomic background 2Health News:What do American babies eat? A lot depends on Mom's socioeconomic background 3Health News:Nutrition Leaders Announces Gift Card Sweepstakes 2Health News:Allred Insurance Satellite Office Grand Opening 2Health News:PreDiabetes Treatment Company Offers PreD Store Shoppers Supplements to Support Healthy Blood Sugar 2Health News:Hormone Therapy May Up Heart-Related Deaths in Some Prostate Cancer Patients 2Health News:Hormone Therapy May Up Heart-Related Deaths in Some Prostate Cancer Patients 3
... social science research organization NORC at the University of Chicago contradicts ... above age 80. It also explains why there ... and above than the Census Bureau predicted there would be as ... a new way of accurately measuring mortality of Americans who are ...
... at NYU Langone Medical Center will present their latest ... tendon, bone and joint at the annual meeting of ... in San Francisco, California. "The introduction ... in clinical care, allows our researchers to identify the ...
... a way to study how our brains assess the behavior ... Their study, described in a paper in the ... to use a computational approach to tease out differing patterns of ... compete against each other in a game, they try to make ...
... At a time when there is tremendous concern about ... and the costs of technology, the Canadian Institutes of ... to improve end of life decision making amongst seriously ... receiving funding for this initiative. , "Canada,s aging population ...
... Institutet, has received a grant of 1.6 million Euro ... the fundamental causes of diabetes. The grant will make ... the release of insulin is regulated in living organisms ... more effective drugs against diabetes. , Diabetes is an ...
... a few years, a new generation of easy-to-use blood-thinning drugs ... are at risk for stroke, according to a journal article ... new drugs do not require patients to come in to ... Nor do the drugs require extensive dietary restrictions. , First ...
Cached Medicine News:Health News:Odds of living a very long life lower than formerly predicted 2Health News:Odds of living a very long life lower than formerly predicted 3Health News:NYU Langone orthopaedic experts present research, clinical advances at AAOS meeting 2Health News:NYU Langone orthopaedic experts present research, clinical advances at AAOS meeting 3Health News:NYU Langone orthopaedic experts present research, clinical advances at AAOS meeting 4Health News:It's not solitaire: Brain activity differs when one plays against others 2Health News:CIHR invests in Queen's-led study on end-of-life decision making 2Health News:Donation opens new opportunities for more effective diabetes treatment 2Health News:Easy-to-use blood thinners likely to replace Coumadin 2
... is enzyme immunoassay kit for the ... concentration in serum. Enzyme immunoassay (EIA) ... many protein hormones in body fluids ... rapid and specific assay. This enzyme ...
SHIONORIA BNP,is a reagent used in the measurement of blood BNP. The blood BNP test allows accurate estimation of coronary functions....
... method for the semi-quantitative determination of ... human serum. The results of the ... an aid in the diagnosis of ... with elevated anti-neutrophil cytoplasmic antibodies (P-ANCA) ...
... The determination of Ang ... in monitoring the pharmacological effect ... variety of angiotensin converting enzyme ... II receptor antagonists as well ...
Medicine Products: